Medication-Assisted Treatment (MAT) | SAMHSA - Substance Abuse and Mental Health Services Administration

Medication-Assisted Treatment (MAT) | SAMHSA - Substance Abuse and Mental Health Services Administration

COVID-19 Guidance for Opioid Treatment Programs

SAMHSA is offering guidance on pharmacotherapy for opioid use disorder availability in circumstances in which patients may be exposed to highly contagious infectious agents (such as COVID-19).

Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT), including opioid treatment programs (OTPs), combines behavioral therapy and medications to treat substance use disorders.

NEW: Read all of SAMHSA's Coronavirus Information

Opioid Treatment Program (OTP) Guidance (March 16, 2020) (PDF | 216 KB)

OTP Guidance for Patients Quarantined at Home with the Coronavirus (PDF | 154 KB)

FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency (PDF | 137 KB)

Sample OTP COVID-19 FAQs (PDF |341 KB)

The Notification of Enforcement Discretion on Telehealth Remote Communications

DEA Information on Telemedicine (PDF | 103 KB)

Use of Telemedicine While Providing Medication-Assisted Treatment (PDF | 146 KB)

DEA Diversion Control Division COVID-19 Information

Tips For Social Distancing, Quarantine, And Isolation During An Infectious Disease Outbreak (PDF | 544 KB)

TAP 34: Disaster Planning Handbook for Behavioral Health Treatment Programs